Copyright
©The Author(s) 2018.
World J Gastroenterol. Jun 28, 2018; 24(24): 2582-2595
Published online Jun 28, 2018. doi: 10.3748/wjg.v24.i24.2582
Published online Jun 28, 2018. doi: 10.3748/wjg.v24.i24.2582
Figure 1 Hepatocellular carcinoma cumulative occurrence rates reported by 11 studies considered in the present review.
HCC: Hepatocellular carcinoma; f.u.: Follow up; NA: Not available.
Figure 2 Hepatocellular carcinoma cumulative recurrence rates reported by 17 studies considered in the present review.
HCC: Hepatocellular carcinoma; f.u.: Follow up; NA: Not available.
- Citation: Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. World J Gastroenterol 2018; 24(24): 2582-2595
- URL: https://www.wjgnet.com/1007-9327/full/v24/i24/2582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i24.2582